Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically documented locally advanced or metastatic NSCLC
Prior platinum-containing regimen or disease recurrence ≤ 6 months since prior platinum-based adjuvant/neoadjuvant regimen.
Measurable disease as defined by RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Life expectancy ≥12 weeks
Adequate hematologic and end-organ function
You may not be if
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
Uncontrolled or symptomatic hypercalcemia
Pregnancy or breastfeeding
Active or history of autoimmune disease or immune deficiency
History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
Severe infection ≤ 4 weeks
Treatment with therapeutic oral or IV antibiotics ≤ 2 weeks prior to study treatment
Significant cardiovascular disease
Prior allogeneic stem cell or solid organ transplantation
Treatment with a live, attenuated vaccine ≤ 4 weeks
Treatment with systemic immunostimulatory agents ≤ 4 weeks or 5 half-lives of the drug
Treatment with systemic immunosuppressive medication ≤ 2 weeks
Tested tumor programmed death-ligand-1 (PD-L1) expression status with an intention to treat the patient if positive
Clareo Health | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
